The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications (Review)

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 3-7

  Economidou, Foteini ^a   Margaritopoulos, George ^a   Antoniou, Kateriaterina M ^a   Siafakasiafakas, Nikolaos M ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Angiogenesis; Pleural effusions

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; ENDOSTATIN; EPHRIN A2; HYALURONIC ACID; PEMETREXED; STROMAL CELL DERIVED FACTOR 1; VANDETANIB; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ARTICLE; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; METASTASIS; NONHUMAN; PATHOGENESIS; PLEURA EFFUSION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 77955651614     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000001     Document Type: Article

References (73)

1. Lee YC and Light RW: Management of malignant pleural effusions. Respirology 9: 148-156, 2004.
2. Antony VE, Loddenkepmper R, Astoul P, et al: Management of malignant pleural effusions. Am J Resp Crit Care Med 162: 1987-2001, 2000.
3. West SD, Davies RJ and Lee YC: Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med 10: 305-310, 2004.
4. Kinasewitz GT: Transudative effusions. Eur Respir J 10: 714-718, 1997.
5. Light RW: Pleural diseases. Dis Mon 38: 261-331, 1992.
6. Yanagama H, Takeuchi E, Suzuki Y, et al: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48: 396-400, 1999.
7. Lee YCG and Lane KB: Cytokines in pleural diseases. In: Textbook of Pleural Disease. Light RW and Lee YCG (eds). Arnold, London, pp63-89, 2003.
8. Light RW: Talc for pleurodesis? Chest 122: 1506-1508, 2002.
9. Yano S, Shinohara H, Herbst RS, et al: Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157: 1893-1903, 2000.
10. Stathopoulos GT, Zhu Z, Everhart MB, et al: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34: 142-150, 2006.
11. Stathopoulos GT, Kollintza A, Moschos C, et al: Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 67: 9825-9834, 2007.
12. Stathopoulos GT, Psallidas I, Moustaki A, et al: Tumor-derived monocyte chemoattractant protein-1 promotes malignant pleural effusion. J Natl Cancer Inst 100: 1464-1476, 2008.
13. Antony VB: Immunological mechanisms in pleural disease. Eur Respir J 21: 539-544, 2003.
14. McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 164: S39-S45, 2001.
15. Hoshino M, Takahashi M and Aoike N: Expression of vascular endothelial growth factor, basic fibroblast growth factor and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 107: 295-301, 2001.
16. Hoshino M, Nakamura Y and Hamid QA: Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 107: 1034-1038, 2000.
17. Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25: 600-604, 2005.
18. Ruiz E, Alemán C, Alegre J, et al: Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung 183: 185-195, 2005.
19. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
20. Cheng D, Rodriguez RM, Perkett EA, et al: Vascular endothelial growth factor in pleural fluid. Chest 116: 760-765, 1999.
21. Grove CS and Lee YC: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8: 294-301, 2002.
22. Yancopoulos GD, Davis S, Gale NW, et al: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
23. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996.
24. Cheng D, Lee YC, Rogers JT, et al: Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. Chest 118: 1747-1753, 2000.
25. Hamed EA, El-Noweihi AM, Mohamed AZ and Mahmoud A: Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 9: 81-86, 2004.
26. Momi H, Matsuyama W, Inoue K, et al: Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med 96: 817-822, 2002.
27. Kalomenidis I, Kollintza A, Sigala I, et al: Angiopoietin-2 levels are elevated in exudative pleural effusions. Chest 129: 1259-1266, 2006.
28. Economidou F, Antoniou KM, Tzanakis N, et al: Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med 102: 774-779, 2008.
29. Duysinx BC, Corhay JL, Hubin L, et al: Diagnostic value of interleukin-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med 102: 1708-1714, 2008.
30. Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284-7290, 2002.
31. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793, 2004.
32. Frederick B, Gustafson D, Bianco C, et al: ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64: 33-37, 2006.
33. Hennequin LF, Stokes ES, Thomas AP, et al: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45: 1300-1312, 2002.
34. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
35. Williams KJ, Telfer BA, Brave S, et al: ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10: 8587-8593, 2004.
36. Matsumori Y, Yano S, Goto H, et al: ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 16: 15-26, 2006.
37. Shibuya K, Komaki R, Shintani T, et al: Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys 69: 1534-1543, 2007.
38. Yano S, Herbst RS, Shinohara H, et al: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6: 957-965, 2000.
39. Wood JM, Bold G, Buchdunger E, et al: PTK 787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000.
40. Li Q, Yano S, Ogino H, et al: The therapeutic efficacy of antivascular endothelial growth factor antibody, bevacizumab and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13: 5918-5925, 2007.
41. Thirkettle I, Harvey P, Hasleton PS, et al: Immunoreactivity for cadherins, HGF/SF, met and erbB-2 in pleural malignant mesotheliomas. Histopathology 36: 522-528, 2000.
42. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. Am J Pathol 193: 468-475, 2001.
43. Dazzi H, Hasleton PS, Thatcher N, et al: Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4 monoclonal antibody. Br J Cancer 61: 924-926, 1990.
44. Thaker PH, Deavers M, Celestino J, et al: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 5145-5150, 2004.
45. Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613-618, 2003.
46. Easty DJ, Herlyn M and Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60: 129-136, 1995.
47. Xu F, Zhong W, Li J, et al: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 25: 2943-2950, 2005.
48. N Nasreen N, Mohammed KA and Antony VB: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 107: 2425-2435, 2006.
49. N Nasreen N, Mohammed KA, Lai Y and Antony VB: Receptor EphA2 activation with ephrin A1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 258: 215-222, 2007.
50. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
51. Nasreen N, Mohammed KA, Sanders K, et al: Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol Res 14: 155-161, 2003.
52. Nasreen N, Mohammed KA, Brown S, et al: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 29: 761-769, 2007.
53. Bourguignon LY, Lokeshwar VB, Chen X and Kerrick WG: Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol 151: 6634-6644, 1993.
54. Nasreen N, Mohammed KA, Hardwick J, et al: Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res 13: 71-78, 2002.
55. Tsigos S, Koutsilieris M and Papapetropoulos A: Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 12: 933-941, 2003.
56. Thurston G, Rudge JS, Ioffe E, et al: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463, 2006.
57. Thurston G, Suri C, Smith K, et al: Leakage-resistant blood vessels in mice trangenically overexpressing angiopoietin-1. Science 286: 2511-2514, 1999.
58. Kim I, Moon SO, Park SK, et al: Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1 and E-selectin expression. Circ Res 89: 477-479, 2001.
59. Gamble JR, Drew J, Trezise L, et al: Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Cir Res 87: 603-607, 2000.
60. Pizurki L, Zhou Z, Glynos K, et al: Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. J Pharmacol 139: 329-336, 2003.
61. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
62. Scharpfenecker M, Fiedler U, Reiss Y and Augustin HG: The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118: 771-780, 2005.
63. Roviezzo F, Tsigkos S, Kotanidou A, et al: Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 314: 738-744, 2005.
64. Tanaka F, Yanagihara K, Otake Y, et al: Prognostic factors in resected pathologic (p-) stage IIIA-N2, non small cell lung cancer. Ann Surg Oncol 11: 612-618, 2004.
65. Tomimoto H, Yano S, Muguruma H, et al: Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. J Med Invest 54: 146-153, 2007.
66. Aiuti A, Tavian M, Cipponi A, et al: Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol 29: 1823-1831, 1999.
67. Feng Y, Broder CC, Kennedy PE and Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane G, protein-coupled receptor. Science 1272: 872-877, 1996.
68. Strieter RM, Belperio JA, Phillips RJ and Keane MP: CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14: 195-200, 2004.
69. Phillips RJ, Burdick MD, Lutz M, et al: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686, 2003.
70. Lee BC, Lee TH, Avraham S and Avraham HK: Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2: 327-338, 2004.
71. Economidou F, Antoniou KM, Proklou A, et al: Investigation of angiogenetic mechanisms in pleural fluid of patients with lung cancer: preliminary results. Am J Respir Cell Mol Biol 179: A2876, 2009.
72. Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35: 233-245, 2004.
73. Oonakahara K, Matsuyama W, Higashimoto I, et al: Stromal-derived factor 1α/CXCL12-CXCR4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 30: 671-677, 2004.